{"data":[{"accessionNo":"0002050709-26-000025","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Squadron Capital Management LLC","reportingCik":null,"personType":"IA,HC","sharesOwned":7350000,"percentOfClass":7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0002050709-26-000025","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Squadron Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":7350000,"percentOfClass":7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0002050709-26-000025","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"Matthew Sesterhenn","reportingCik":null,"personType":"HC,IN","sharesOwned":7350000,"percentOfClass":7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0002050709-26-000025","formType":"SCHEDULE 13G/A","amendmentNo":3,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common stock, $0.001 par value per share","eventDate":"2026-06-30","reportingPerson":"William Blank","reportingCik":null,"personType":"HC,IN","sharesOwned":7350000,"percentOfClass":7,"filedAt":"2026-08-14","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0002012383-26-002872","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS INC","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock","eventDate":"2026-06-30","reportingPerson":"BlackRock, Inc.","reportingCik":null,"personType":"HC","sharesOwned":7352913,"percentOfClass":7,"filedAt":"2026-07-29","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001104659-26-076490","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-16","reportingPerson":"Millennium Management LLC","reportingCik":null,"personType":"OO","sharesOwned":4567952,"percentOfClass":4.4,"filedAt":"2026-06-22","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001104659-26-076490","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-16","reportingPerson":"Millennium Group Management LLC","reportingCik":null,"personType":"OO","sharesOwned":4567952,"percentOfClass":4.4,"filedAt":"2026-06-22","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001104659-26-076490","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-06-16","reportingPerson":"Israel A. Englander","reportingCik":null,"personType":"IN","sharesOwned":4567952,"percentOfClass":4.4,"filedAt":"2026-06-22","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001738048-26-000066","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-02","reportingPerson":"Venrock Healthcare Capital Partners III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":6508433,"percentOfClass":6.2,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001738048-26-000066","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-02","reportingPerson":"VHCP Co-Investment Holdings III, LLC","reportingCik":null,"personType":"OO","sharesOwned":6508433,"percentOfClass":6.2,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001738048-26-000066","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-02","reportingPerson":"Venrock Healthcare Capital Partners EG, L.P.","reportingCik":null,"personType":"PN","sharesOwned":6508433,"percentOfClass":6.2,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001738048-26-000066","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-02","reportingPerson":"VHCP Management III, LLC","reportingCik":null,"personType":"OO","sharesOwned":6508433,"percentOfClass":6.2,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001738048-26-000066","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-02","reportingPerson":"VHCP Management EG, LLC","reportingCik":null,"personType":"OO","sharesOwned":6508433,"percentOfClass":6.2,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001738048-26-000066","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-02","reportingPerson":"Nimish Shah","reportingCik":null,"personType":"IN","sharesOwned":6508433,"percentOfClass":6.2,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001738048-26-000066","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, $0.001 par value per share","eventDate":"2026-06-02","reportingPerson":"Bong Y. Koh","reportingCik":null,"personType":"IN","sharesOwned":6508433,"percentOfClass":6.2,"filedAt":"2026-06-09","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0000919574-26-002929","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":4763158,"percentOfClass":4.54,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0000919574-26-002929","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":4763158,"percentOfClass":4.54,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0000919574-26-002929","formType":"SCHEDULE 13G/A","amendmentNo":1,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common Stock, par value $0.001 per share","eventDate":"2026-03-31","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":4763158,"percentOfClass":4.54,"filedAt":"2026-05-13","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001831942-26-000017","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common stock, $0.001 par value per share","eventDate":"2026-04-27","reportingPerson":"Commodore Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":5505527,"percentOfClass":5.1,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001831942-26-000017","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common stock, $0.001 par value per share","eventDate":"2026-04-27","reportingPerson":"Commodore Capital Master LP","reportingCik":null,"personType":"PN","sharesOwned":5505527,"percentOfClass":5.1,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001831942-26-000017","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common stock, $0.001 par value per share","eventDate":"2026-04-27","reportingPerson":"Robert Egen Atkinson","reportingCik":null,"personType":"HC,IN","sharesOwned":5505527,"percentOfClass":5.1,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001831942-26-000017","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":"75955J402","securityClass":"Common stock, $0.001 par value per share","eventDate":"2026-04-27","reportingPerson":"Michael Kramarz","reportingCik":null,"personType":"HC,IN","sharesOwned":5505527,"percentOfClass":5.1,"filedAt":"2026-05-04","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0002050709-26-000007","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock ($.001 par value)","eventDate":"2025-12-31","reportingPerson":"Squadron Master Fund LP","reportingCik":null,"personType":"PN","sharesOwned":7395510,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0002050709-26-000007","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock ($.001 par value)","eventDate":"2025-12-31","reportingPerson":"Squadron Capital Management LLC","reportingCik":null,"personType":"IA,HC","sharesOwned":7395510,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0002050709-26-000007","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock ($.001 par value)","eventDate":"2025-12-31","reportingPerson":"William Blank","reportingCik":null,"personType":"HC,IN","sharesOwned":7395510,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0002050709-26-000007","formType":"SCHEDULE 13G/A","amendmentNo":2,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock ($.001 par value)","eventDate":"2025-12-31","reportingPerson":"Matthew Sesterhenn","reportingCik":null,"personType":"HC,IN","sharesOwned":7395510,"percentOfClass":9.9,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0000902664-26-001027","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Alex R. Rosen","reportingCik":null,"personType":"HC,IN","sharesOwned":4086181,"percentOfClass":5.57,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0000902664-26-001027","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Simon Basseyn","reportingCik":null,"personType":"HC,IN","sharesOwned":4086181,"percentOfClass":5.57,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0000902664-26-001027","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Spruce Street Capital LP","reportingCik":null,"personType":"IA,PN","sharesOwned":4086181,"percentOfClass":5.57,"filedAt":"2026-02-17","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0000902664-26-000914","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Adage Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":4270000,"percentOfClass":5.82,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0000902664-26-000914","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Robert Atchinson","reportingCik":null,"personType":"HC,IN","sharesOwned":4270000,"percentOfClass":5.82,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0000902664-26-000914","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock, par value $0.001 per share","eventDate":"2025-12-31","reportingPerson":"Phillip Gross","reportingCik":null,"personType":"HC,IN","sharesOwned":4270000,"percentOfClass":5.82,"filedAt":"2026-02-12","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001274173-26-000046","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"RELMADA THERAPEUTICS, INC.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock","eventDate":"2026-01-30","reportingPerson":"JANUS HENDERSON GROUP PLC","reportingCik":null,"personType":"HC","sharesOwned":7439415,"percentOfClass":10.1,"filedAt":"2026-02-06","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001193125-25-283441","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock, par value $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Ikarian Capital, LLC","reportingCik":null,"personType":"IA","sharesOwned":3543359,"percentOfClass":4.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"},{"accessionNo":"0001193125-25-283441","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001553643","issuerName":"Relmada Therapeutics, Inc.","ticker":"RLMD","cusip":null,"securityClass":"Common Stock, par value $0.001 par value per share","eventDate":"2025-09-30","reportingPerson":"Neil Shahrestani","reportingCik":null,"personType":"IN,HC","sharesOwned":3543359,"percentOfClass":4.8,"filedAt":"2025-11-14","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd"}],"updatedAt":"2026-11-05T14:33:41.043Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/rlmd","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}